These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31216324)

  • 81. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.
    Nauck MA; Weber I; Bach I; Richter S; Orskov C; Holst JJ; Schmiegel W
    Diabet Med; 1998 Nov; 15(11):937-45. PubMed ID: 9827848
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists.
    Cuthbertson DJ; Irwin A; Gardner CJ; Daousi C; Purewal T; Furlong N; Goenka N; Thomas EL; Adams VL; Pushpakom SP; Pirmohamed M; Kemp GJ
    PLoS One; 2012; 7(12):e50117. PubMed ID: 23236362
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients.
    Montvida O; Klein K; Kumar S; Khunti K; Paul SK
    Diabetes Obes Metab; 2017 Jan; 19(1):108-117. PubMed ID: 27629433
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis.
    Qian D; Zhang T; Tan X; Zheng P; Liang Z; Xie J; Jiang J; Situ B
    PLoS One; 2018; 13(8):e0202563. PubMed ID: 30148851
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins.
    Hasegawa Y; Hori M; Nakagami T; Harada-Shiba M; Uchigata Y
    J Clin Lipidol; 2018; 12(1):62-69.e1. PubMed ID: 29217412
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland.
    Caparrotta TM; Blackbourn LAK; McGurnaghan SJ; Chalmers J; Lindsay R; McCrimmon R; McKnight J; Wild S; Petrie JR; Philip S; McKeigue PM; Webb DJ; Sattar N; Colhoun HM;
    Diabetes Care; 2020 Sep; 43(9):2034-2041. PubMed ID: 32581068
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Third-Line Antidiabetic Therapy Intensification Patterns and Glycaemic Control in Patients with Type 2 Diabetes in the USA: A Real-World Study.
    Koye DN; Montvida O; Paul SK
    Drugs; 2020 Apr; 80(5):477-487. PubMed ID: 32141024
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Patterns and predictors of long-term weight change in patients with type 2 diabetes mellitus.
    Janghorbani M; Amini M
    Ann Nutr Metab; 2009; 54(2):111-8. PubMed ID: 19295194
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity.
    Babenko AY; Savitskaya DA; Kononova YA; Trofimova AY; Simanenkova AV; Vasilyeva EY; Shlyakhto EV
    J Diabetes Res; 2019; 2019():1365162. PubMed ID: 30944827
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Real-world impact on monthly glucose-lowering medication cost, HbA
    Rose TN; Jacobs ML; Reid DJ; Bouwmeester CJ; Conley MP; Fatehi B; Matta TM; Barr JT
    J Am Pharm Assoc (2003); 2020; 60(1):31-38.e1. PubMed ID: 31611005
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate.
    Sardu C; Paolisso P; Sacra C; Santamaria M; de Lucia C; Ruocco A; Mauro C; Paolisso G; Rizzo MR; Barbieri M; Marfella R
    Cardiovasc Diabetol; 2018 Oct; 17(1):137. PubMed ID: 30348145
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK.
    Boye KS; Stein D; Matza LS; Jordan J; Yu R; Norrbacka K; Hassan SW; García-Pérez LE
    Drugs R D; 2019 Jun; 19(2):213-225. PubMed ID: 31115873
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Are behavioural approaches feasible and effective in the treatment of type 2 diabetes? A propensity score analysis vs. prescriptive diet.
    Forlani G; Lorusso C; Moscatiello S; Ridolfi V; Melchionda N; Di Domizio S; Marchesini G
    Nutr Metab Cardiovasc Dis; 2009 Jun; 19(5):313-20. PubMed ID: 18722095
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients.
    Fadini GP; Simioni N; Frison V; Dal Pos M; Bettio M; Rocchini P; Avogaro A
    Acta Diabetol; 2013 Dec; 50(6):943-9. PubMed ID: 23754673
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
    Diamant M; Van Gaal L; Guerci B; Stranks S; Han J; Malloy J; Boardman MK; Trautmann ME
    Lancet Diabetes Endocrinol; 2014 Jun; 2(6):464-73. PubMed ID: 24731672
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials.
    Wang Y; Li L; Yang M; Liu H; Boden G; Yang G
    Diabetes Obes Metab; 2011 Nov; 13(11):972-81. PubMed ID: 21651690
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
    Kosiborod M; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Birkeland KI; Jørgensen ME; Thuresson M; Arya N; Bodegård J; Hammar N; Fenici P;
    Circulation; 2017 Jul; 136(3):249-259. PubMed ID: 28522450
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Effect of Bariatric Surgery on Cardiovascular Events and Metabolic Outcomes in Obese Patients with Insulin-Treated Type 2 Diabetes: a Retrospective Cohort Study.
    Alkharaiji M; Anyanwagu U; Donnelly R; Idris I
    Obes Surg; 2019 Oct; 29(10):3154-3164. PubMed ID: 31392579
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Exenatide Once Weekly: Effectiveness, Tolerability, and Discontinuation Predictors in a Real-world Setting.
    Di Dalmazi G; Coluzzi S; Baldassarre MPA; Sorbo SE; Dell'Aquila S; Febo F; Ginestra F; Graziano G; Rossi MC; Consoli A; Formoso G
    Clin Ther; 2020 Sep; 42(9):1738-1749.e1. PubMed ID: 32753164
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Weight and glycaemic control in type 2 diabetes: what is the outcome of insulin initiation?
    Watson L; Wilson BP; Alsop J; Kumar S
    Diabetes Obes Metab; 2011 Sep; 13(9):823-31. PubMed ID: 21481128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.